Doctor Care Anywhere Group (ASX:DOC) Full Year 2024 Results
Key Financial Results
- Revenue: UK£39.3m (up 2.3% from FY 2023).
- Net loss: UK£5.14m (loss narrowed by 37% from FY 2023).
- UK£0.014 loss per share (improved from UK£0.022 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Doctor Care Anywhere Group Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 3.6%. Earnings per share (EPS) also missed analyst estimates by 142%.
Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 22% growth forecast for the Healthcare Services industry in Australia.
Performance of the Australian Healthcare Services industry.
The company's shares are up 2.3% from a week ago.
Risk Analysis
Be aware that Doctor Care Anywhere Group is showing 2 warning signs in our investment analysis and 1 of those is significant...
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About ASX:DOC
Doctor Care Anywhere Group
Provides digital healthcare and development services in the United Kingdom, Australia, and the Republic of Ireland.
Undervalued with high growth potential.
Market Insights
Community Narratives

